Promising antidiabetic drug

We have started an interesting study with a promising antidiabetic drug. The drug is designed in the form of prolonged-action tablets, which action leads to increased insulin secretion. It is an innovative drug that is in the first phase of research when it is first used in humans. The first drug administrations are behind us, we continue with the next doses. We plan to complete 1 part of SAD (single ascending dose) at the end of July.

More and more people are suffering from type II diabetes, it is a civilization disease, we challenge it with new drugs in the hope of full success. The BRG Center hopes to participate in many such Polish projects.

Go back

News

Phase IIa diabetes study termination

We have succesfully completed phase II study for patients suffered from diabetes type II.

Read more …

Rivaroxaban bioequivalence studies

Our site has completed 5 bioequivalence studies with Rivaroxaban. The studies were conducted in our 1st phase unit in Kajetany.

Read more …

Clinical study with cladribine completed

We have succesfully completed phase I study for female patients suffering from multiple sclerosis.

Read more …

31st Great Final of WOŚP

31st Great Final of Wielka Orkiestra Świątecznej Pomocy.

Lets play till the end of the world and one day longer!

Read more …

Merry Christmas

We wish you Merry Christmas and Happy New Year!

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲